Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Smith

Showing results (211-220 of 303) with videos related to

Pageof 31
Sort By:
Leukemia & Lymphoma|February 6, 2023
Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary diseaseKhaled Sanber, Kevin Ye, Hua-Ling Tsai, et al.
Cancer|August 19, 2007
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cellsMichael W N Deininger, Jorge Cortes, Ron Paquette, et al.
Arthritis Care & Research|November 12, 2015
ReplyJanet E Pope, Naomi F Rothfield, Rosalind Ramsey-Goldman, et al.
British Journal of Haematology|May 19, 2012
Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemiasAmer M Zeidan, Rebecca M Ricklis, Hetty E Carraway, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemiasJudith E Karp, Antonino Passaniti, Ivana Gojo, et al.
Blood|January 21, 2012
A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemiaJonathan M Gerber, B Douglas Smith, Brownhilda Ngwang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 MutationsDaniel A Pollyea, Courtney D DiNardo, Martha L Arellano, et al.
Science Translational Medicine|June 12, 2015
Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemiaYiting Lim, Lukasz Gondek, Li Li, et al.
Leukemia Research|December 8, 2009
Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemiaJudith E Karp, Amanda Blackford, B Douglas Smith, et al.
Blood|March 24, 2005
Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabineRuben A Mesa, David Loegering, Heather L Powell, et al.
Pageof 31

Showing results (211-220 of 303) with videos related to

Sort By:
Pageof 31
Leukemia & Lymphoma|February 6, 2023
Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary diseaseKhaled Sanber, Kevin Ye, Hua-Ling Tsai, et al.
Cancer|August 19, 2007
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cellsMichael W N Deininger, Jorge Cortes, Ron Paquette, et al.
Arthritis Care & Research|November 12, 2015
ReplyJanet E Pope, Naomi F Rothfield, Rosalind Ramsey-Goldman, et al.
British Journal of Haematology|May 19, 2012
Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemiasAmer M Zeidan, Rebecca M Ricklis, Hetty E Carraway, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemiasJudith E Karp, Antonino Passaniti, Ivana Gojo, et al.
Blood|January 21, 2012
A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemiaJonathan M Gerber, B Douglas Smith, Brownhilda Ngwang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 MutationsDaniel A Pollyea, Courtney D DiNardo, Martha L Arellano, et al.
Science Translational Medicine|June 12, 2015
Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemiaYiting Lim, Lukasz Gondek, Li Li, et al.
Leukemia Research|December 8, 2009
Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemiaJudith E Karp, Amanda Blackford, B Douglas Smith, et al.
Blood|March 24, 2005
Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabineRuben A Mesa, David Loegering, Heather L Powell, et al.
Pageof 31